|
||
| |||||||
|
Multiple Myeloma update with ASH highlights Increasing the Therapeutic Option Introduction Currently available therapies for multiple myeloma is effective in high dose, but is associated with severe toxicity. In addition, all patients eventually relapse. This has resulted in a market ready for the entry of low toxicity therapies and drugs that will increase response rates and maintain remission. Scope Detailed coverage of patient potential across the seven major markets, as well as analysis of the main unmet needs. Discussion and analysis of the hot topics presented at this year’s leading oncology conferences, including ASH (American Society of Hematology) Overview and analysis of the treatment of multiple myeloma, including and in-depth analysis of the currently used drug regimens. Comprehensive analysis of key late-stage products, with Datamonitor forecasts of drug revenues to 2010. Report Highlights No new drugs have been approved for the treatment of multiple myeloma in two decades, leaving physicians using the non-pharmacological means to improve efficacy of treatment. Consequently, physicians are eagerly awaiting the new generation of biotechnology manufacturer’s drugs. Celgene’s Thalomid, Aventis’ Genasense and Millennium’s Velcade will be the first market entrants, but high volume use still awaits subsequent market entrants. Reasons to Purchase Understand the factors that affect hematologists' treatment options and prescribing decisions Identify areas of the multiple myeloma market that are currently under-served by competitors Benchmark current developmental drugs against an analysis of the current gold standard MP and VAD regimens Leverage your competitive advantages by accessing assessments of all phase III pipeline drugs Enhance sales forecasting and product positioning using Datamonitor’s scenario based sales and epidemiological forecasts Publisher: Datamonitor Oncology Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Datamonitor_Oncology.html#a275 |
|
|
